PARP抑制剂治疗去势抵抗性前列腺癌的研究进展

近年来随着基因组测序研究的进展使恶性肿瘤的精准治疗不断深入。针对合并特定的DNA损伤修复基因(DNA repair genes,DRGs)突变,包括同源重组介导修复(homologous recombin-mediated repair,HRR)基因突变的前列腺癌症患者,多聚腺苷酸二磷酸核糖聚合酶抑制剂(Poly ADP-ribose polymerase inhibitor,PARPi)可通过抑制DNA的修复介导存在该类基因突变的肿瘤细胞死亡。自2014年PARP抑制剂被首先批准用于晚期卵巢癌以来,针对DNA损伤修复基因突变和PARPi的研究不断进行,如今PARPi在前列腺癌患者尤其是转移性去势抵抗性前列腺癌(mCRPC)的治疗中表现不俗。本文就PARPi在mCRPC患者中的应用作一综述,对已发表和正在进行的临床试验结果进行讨论,为前列腺癌患者的个性化治疗提供更好的临床证据。

Progress of PARP inhibitors in the treatment of castration-resistant prostate cancer

In recent years,with the progress of genome sequencing research,the precision treatment of malignant tumors has been continuously deepened.For prostate cancer patients with mutations in specific DNA damage repair genes(DRGs),included homologous recombination-mediated repair(HRR) gene mutations,poly ADP-ribose polymerase inhibitor(PARPi) can inhibit DNA repair mediates the death of tumor cells with such gene mutations.Since PARP inhibitors were first approved for advanced ovarian cancer in 2014,research on DNA damage repair gene mutations and PARPi has continued.PARPi is performing well in the treatment of prostate cancer patients,especially metastatic castration-resistant prostate cancer(mCRPC) based on current evidence.This review focuses on the published and ongoing research on the application of PARPi in mCRPC patients to provide better clinical evidence for the personalized treatment of prostate cancer patients.